First patient enrolled in MIMICS-3 USA study

1615
BioMimics 3D stent

Veryan Medical recently announced that the first patient has been enrolled in the MIMICS-3 USA study by John H Rundback at NJ Endovascular & Amputation Prevention (Clifton, USA). 

Nick Yeo, Veryan’s CEO commented, “We are enormously grateful to Dr Rundback and all of the team at NJ Endovascular & Amputation Prevention for the professional and efficient way they have helped Veryan reach this significant milestone so soon after US product launch in September 2020. The MIMICS-3D USA registry will grow our clinical database on BioMimics 3D use to more than 1,750 patients and will improve the opportunity for physicians across the world to have access to safety and effectiveness data on the BioMimics 3D vascular stent system, including those from a pivotal study with three-year follow-up.”

Rundback stated, “We have been excited to be involved in this study based upon the impressive clinical data for BioMimics 3D, and the unique helical centreline which creates a swirling flow pattern that promotes arterial healing after intervention. In addition, the truly biometric design addresses the unique physical challenges and mechanical stresses inherent in the femoropopliteal arteries. We look forward to continuing to collaborate with the Veryan team as we enrol patients to further enhance the real-world data on the value of the BioMimics 3D stent technology.”

The MIMICS-3D USA study will evaluate safety, effectiveness, and device performance of the BioMimics 3D stent within a real-world clinical population of patients undergoing femoropopliteal intervention. The study will enrol 500 patients from 40 sites within a two-year recruitment period and the three coordinating principal investigators are interventional cardiologist Sahil Parikh (Columbia University Medical Center, Columbia, USA), vascular surgeon Miguel Montero (Baylor College of Medicine, Houston, USA), and interventional radiologist Robert Beasley (Mount Sinai Medical Center, Miami, USA).


LEAVE A REPLY

Please enter your comment!
Please enter your name here